In a public interest litigation in 2013 it was brought to light that in India, between 2009 and 2010, GSK allegedly tested cervical cancer vaccinations on girls from disadvantaged groups without obtaining the consent of the parents. During this trial seven girls died and no measures were taken to prevent their deaths1. In 2012 in Argentina, GSK was fined for conducting pneumonia vaccine trials between 2007 and 2008, which supposedly caused the death of 14 babies2. Moreover, the company was condemned for using the illiteracy of some parents to their advantage in order to gain the authorisation needed to conduct clinical trials.
In June 2013 it came to light that GSK had been improperly conducting clinical trials for a multiple sclerosis drug at their research centre in Shanghai without concluding the necessary animal testing beforehand3.
- Reprisk (2014): Insight – ESG Risk in the Corporate World – Issue #06 Pharmaceuticals (accessed 25.08.2014) [↩]
- Tajan, J. C. (2012): GSK fined over vaccine trials; 14 babies reported dead. – Buenos Aires Herald , 3 January (accessed 25.08.2014) [↩]
- Reprisk (2014): Insight – ESG Risk in the Corporate World – Issue #06 Pharmaceuticals; (accessed 25.08.2014) [↩]